Multicenter evaluation demonstrates improved outcomes in hepatocellular carcinoma surveillance using updated AASLD guidelines, indicating enhanced patient care.
American Association for the Study of Liver Diseases (AASLD) version 2023, which incorporates visualization score VIS-C, increasing α-fetoprotein level, and lesion growth, improved sensitivity and negative predictive value for hepatocellular carcinoma surveillance, outperforming US Liver Imaging Reporting System version 2017 and AASLD version 2018.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: